PubRank

David E Elder

Author PubWeight™ 98.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 2005 7.86
2 Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res 2003 4.03
3 Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009 3.89
4 Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008 3.79
5 Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists. J Cutan Pathol 2004 3.43
6 Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009 2.85
7 MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006 2.84
8 Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet 2009 2.65
9 High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006 2.40
10 An atypical melanocytic lesion without genomic abnormalities shows locoregional metastasis. J Cutan Pathol 2012 2.31
11 Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet 2011 2.29
12 Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2006 2.17
13 Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007 2.06
14 Identifying individuals at high risk of melanoma: a practical predictor of absolute risk. J Clin Oncol 2006 2.05
15 Diet and melanoma in a case-control study. Cancer Epidemiol Biomarkers Prev 2004 2.05
16 Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther 2008 1.86
17 Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 2005 1.84
18 MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008 1.72
19 State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol 2010 1.68
20 Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002 1.68
21 Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010 1.47
22 Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nat Genet 2011 1.46
23 Average midrange ultraviolet radiation flux and time outdoors predict melanoma risk. Cancer Res 2002 1.42
24 Does MC1R genotype convey information about melanoma risk beyond risk phenotypes? Cancer 2010 1.34
25 The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes. Am J Pathol 2009 1.31
26 Relationship between sun exposure and melanoma risk for tumours in different body sites in a large case-control study in a temperate climate. Eur J Cancer 2011 1.24
27 Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol 2008 1.19
28 A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet 2013 1.17
29 Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther 2006 1.16
30 P gene as an inherited biomarker of human eye color. Cancer Epidemiol Biomarkers Prev 2002 1.15
31 Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 2005 1.11
32 Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer 2006 1.08
33 Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005 1.06
34 Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 2010 1.05
35 Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations. Am J Surg Pathol 2013 1.05
36 Multiple primary melanoma revisited. Cancer 2002 1.02
37 Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol 2007 1.02
38 Predictors of regional nodal disease in patients with thin melanomas. Ann Surg Oncol 2006 1.00
39 Histomorphologic assessment and interobserver diagnostic reproducibility of atypical spitzoid melanocytic neoplasms with long-term follow-up. Am J Surg Pathol 2014 0.99
40 Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas. Am J Surg Pathol 2002 0.98
41 Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006 0.96
42 Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol 2008 0.94
43 Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. Cancer Res 2004 0.94
44 A practical approach to selected problematic melanocytic lesions. Am J Clin Pathol 2004 0.93
45 Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2006 0.93
46 Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy. Ann Surg Oncol 2013 0.93
47 Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 2004 0.92
48 High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol 2011 0.92
49 Sunbeds and sunlamps: who used them and their risk for melanoma. Pigment Cell Melanoma Res 2011 0.92
50 Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi. Am J Dermatopathol 2004 0.92
51 Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 2011 0.90
52 Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol 2013 0.86
53 Reliability and validity of a histologic score as a marker for skin cancer chemoprevention studies. Anal Quant Cytol Histol 2003 0.86
54 Gene expression profiling of melanocytic lesions. Am J Dermatopathol 2003 0.85
55 Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions. Int J Cancer 2014 0.84
56 Outcomes of atypical spitz tumors with chromosomal copy number aberrations and conventional melanomas in children. Am J Surg Pathol 2013 0.84
57 Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med 2003 0.82
58 A case of sweet syndrome with spleen and lymph node involvement preceded by parvovirus B19 infection, and a review of the literature on extracutaneous sweet syndrome. Am J Dermatopathol 2010 0.81
59 Incomplete biopsy of melanocytic lesions can impair the accuracy of pathological diagnosis. Australas J Dermatol 2006 0.81
60 Lymphatic invasion predicts aggressive behavior in melanocytic tumors of uncertain malignant potential (MELTUMP). Am J Surg Pathol 2013 0.78
61 Frontiers in melanocytic pathology. Pathology 2004 0.78
62 Update on Thin Melanoma: Outcome of an International Workshop. Adv Anat Pathol 2016 0.77
63 Prognosis of patients with melanoma and microsatellitosis undergoing sentinel lymph node biopsy. Ann Surg Oncol 2013 0.75
64 Validation of prognostic models for melanoma. Am J Clin Pathol 2002 0.75
65 Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma. Methods Mol Biol 2014 0.75
66 Cellular nodules in congenital pattern nevi. J Cutan Pathol 2004 0.75
67 Angiomatoid Spitz nevus: a clinicopathological study of six cases and a review of the literature. J Cutan Pathol 2009 0.75
68 Pathologists' Use of Second Opinions in Interpretation of Melanocytic Cutaneous Lesions: Policies, Practices, and Perceptions. Dermatol Surg 2017 0.75
69 Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res 2006 0.75
70 Smooth muscle hamartoma associated with a congenital pattern melanocytic nevus, a case report and review of the literature. J Cutan Pathol 2008 0.75